John Overdeck’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.78M | Buy |
2,436,673
+1,138,872
| +88% | +$1.36M | ﹤0.01% | 2695 |
|
|
2026
Q1 | $1.8M | Buy |
1,297,801
+1,207,182
| +1,332% | +$1.66M | ﹤0.01% | 2834 |
|
|
2025
Q4 | $146K | Buy |
+90,619
| New | +$190K | ﹤0.01% | 3810 |
|
|
2024
Q4 | – | Sell |
-24,848
| Closed | -$32.8K | – | 3176 |
|
|
2024
Q3 | $32.8K | Buy |
+24,848
| New | +$33.2K | ﹤0.01% | 2991 |
|
|
2024
Q1 | – | Sell |
-185,399
| Closed | -$230K | – | 3004 |
|
|
2023
Q4 | $230K | Buy |
185,399
+157,938
| +575% | +$161K | ﹤0.01% | 2780 |
|
|
2023
Q3 | $31.3K | Sell |
27,461
-188,752
| -87% | -$242K | ﹤0.01% | 2847 |
|
|
2023
Q2 | $198K | Buy |
+216,213
| New | +$209K | ﹤0.01% | 2646 |
|
|
2023
Q1 | – | Sell |
-374,289
| Closed | -$216K | – | 2935 |
|
|
2022
Q4 | $216K | Sell |
374,289
-163,072
| -30% | -$51.1K | ﹤0.01% | 2368 |
|
|
2022
Q3 | $170K | Buy |
537,361
+323,812
| +152% | +$127K | ﹤0.01% | 2143 |
|
|
2022
Q2 | $75K | Buy |
+213,549
| New | +$89.6K | ﹤0.01% | 2302 |
|
|
2022
Q1 | – | Sell |
-97,174
| Closed | -$220K | – | 2606 |
|
|
2021
Q4 | $220K | Buy |
+97,174
| New | +$265K | ﹤0.01% | 3853 |
|
|
2021
Q2 | – | Sell |
-626,577
| Closed | -$2.12M | – | 3983 |
|
|
2021
Q1 | $2.12M | Buy |
626,577
+105,734
| +20% | +$381K | 0.01% | 1663 |
|
|
2020
Q4 | $1.46M | Buy |
+520,843
| New | +$1.52M | ﹤0.01% | 1718 |
|
|
2020
Q3 | – | Sell |
-389,443
| Closed | -$5.29M | – | 3041 |
|
|
2020
Q2 | $5.29M | Buy |
389,443
+369,616
| +1,864% | +$3.82M | 0.03% | 621 |
|
|
2020
Q1 | $150K | Buy |
19,827
+1,777
| +10% | +$13.8K | ﹤0.01% | 2744 |
|
|
2019
Q4 | $114K | Buy |
+18,050
| New | +$85.8K | ﹤0.01% | 3513 |
|
|
2019
Q2 | – | Sell |
-83,546
| Closed | -$684K | – | 3285 |
|
|
2019
Q1 | $684K | Sell |
83,546
-53,309
| -39% | -$366K | ﹤0.01% | 2061 |
|
|
2018
Q4 | $757K | Buy |
136,855
+97,719
| +250% | +$765K | ﹤0.01% | 1826 |
|
|
2018
Q3 | $346K | Buy |
39,136
+16,672
| +74% | +$149K | ﹤0.01% | 2680 |
|
|
2018
Q2 | $224K | Sell |
22,464
-535
| -2% | -$5.36K | ﹤0.01% | 3088 |
|
|
2018
Q1 | $219K | Buy |
+22,999
| New | +$322K | ﹤0.01% | 2940 |
|
|
2017
Q4 | – | Sell |
-154,293
| Closed | -$3.04M | – | 3050 |
|
|
2017
Q3 | $3.04M | Buy |
154,293
+115,208
| +295% | +$1.77M | 0.01% | 1073 |
|
|
2017
Q2 | $562K | Buy |
+39,085
| New | +$495K | ﹤0.01% | 2255 |
|
Other funds holding AKBA
John Overdeck's AKBA Position: Q2 2026 in Review
John Overdeck increased its Akebia Therapeutics (AKBA) stake by 88% in Q2 2026, buying an estimated $1.36M and bringing the position to 2,436,673 shares worth $2.78M. The position accounts for ﹤0.01% of the portfolio, ranked #2695.
John Overdeck first reported a position in AKBA in Q2 2017 and has held it in 23 quarters since. The position peaked at $5.29M in Q2 2020. 169 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.
- John Overdeck held 2,436,673 shares of Akebia Therapeutics worth $2.78M as of Q2 2026.
- John Overdeck bought 1,138,872 Akebia Therapeutics shares in Q2 2026, an estimated $1.36M.
- Akebia Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2695 holding.
- John Overdeck first reported a position in Akebia Therapeutics in Q2 2017 and has held it in 23 quarters since.
- John Overdeck's Akebia Therapeutics position peaked at $5.29M in Q2 2020.
- 169 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.